Avi Biopharma Inc
(AVII) 2.15

One SW Columbia St, Suite 1105, Portland, OR 97258

AVI BioPharma, Inc. develps therapeutic products with main focus on the treatment of cancer and heart disease. The company develops products based on two leading platforms, Cancer Immunotherapy and NEU-GENES. The company focuses its three platform technologies on two important clinical areas, cancer and cardiovascular disease. Neu-Genes(R), a patented class of antisense compounds are developed by the company which may prove to be useful in the treatment of a wide range of human diseases. Another innovation of the company, intracellular drug delivery technology, CytoPorter(TM), which may be useful with many FDA-approved drugs as well as drugs in development. The company operates in the United States, Canada, Europe, Australia and Japan.

Biohesion, Inc.
*VENDOR*

1208 NE 100th Street, Seattle WA, 98125

Biohesion is developing products & technology to improve protein / molecular binding to inert surfaces including gold. Supporting high value applications in discovery research, biosensor development, clinical and IVD diagnostics, environmental monitoring and other areas. The Company also offers a custom cloning and protein expression service.

Cell Therapeutics Inc
(CTIC) 0.39

201 Elliott Avenue West Suite 400, Seattle, WA 98119

Cell Therapeutics, Inc. Acquired NovusPharma in June 2003. Cell Therapeutics is developing, acquiring, commercializing novel treatments for cancer. The research and in-licensing activities of the Company are concentrated on identifying new, less taxic and more effective ways to treat cancer. In October 2000 the company launched Trisenox, a pharmaceutical grade arsenic product that has been approved by the FDA to treat patients with relapsed or refractory acute promyelocytic Leukemia. The principal products of the Company includes TRISENOX, PG-TXL, PG- CPT AND CT-2584.

CellCyte Genetics Corp.
(CCYG.OB) 0.02

5400 Carillon Point, Kirkland, WA 98033

CellCyte is developing clinical-stage therapeutic agents and treatments for oncology, diabetes, heart, liver, lung and kidney diseases as well as for stem cell bone marrow and organ transplants. Our discoveries have demonstrated the potential to yield a dominant portfolio of new, innovative and safe stem cell regimens without using embryonic stem cells. These scientific discoveries are the first stem cell enabling drugs and as such are the first ever to enter FDA clinical trials. They are product-based compounds and will be supplied in a single use vial form for intravenous administration. The magnitude of these discoveries offer applicability across a number of diseases and could open the long awaited door for safe stem cell treatments and improve survival from many of the worlds’ most pervasive diseases. In addition, the company has a new method for early adenocarcinoma tumor detection that can detect breast and ovarian tumors less than the size of a grain of rice(2mm), and that has already shown encouraging results in a Phase I clinical trial.

CEPTYR

12277 134th Ct. NE, Suite 100, Redmond, WA 98052

CEPTYR,® Inc., was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored domain in pharmaceutical development. We assembled the world’s leading experts in this field. Excellent progress has been made in identifying compelling PTP targets, and in novel chemistry for inhibitor drugs. Our first disease targeted is diabetes and obesity.

CombiMatrix
*VENDOR/SERVICE*

6500 Harbour Heights Pkwy, Suite 301, Mukilteo, WA 98275

CombiMatrix’s patented electrochemical manufacturing process utilizes standard semiconductor technology, proprietary software, and chemistry to build arrays of materials -- molecule by molecule. The company’s CustomArray(TM) products are DNA microarrays, which have uses in pharmaceutical, diagnostic, biotech, and agrochemical industries as well as in research and government markets. The company also uses its technology in synergistic internal programs for diagnostics, drug development, and biodefense in addition to partnerships for nanomaterials development.

Corixa Corp

1124 Columbia Street Suite 200, Seattle, WA 98104-2040

Corixa Corporation is a developer of immunotherapies with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. The Company has a broad range of technology platforms, which enable both integrated vaccine product design and the use of its separate proprietary technologies (antigens, monoclonal antibodies, adjuvants, antigen delivery technology and tumor activated peptide, or TAP, pro-drug technology) on a standalone, POWERED BY CORIXA basis. The Company exploits its expertise in immunology and its proprietary technology platforms to discover and develop vaccines, antigen-based products, including therapeutic antibodies, novel adjuvants and targeted oncologics.

Dendreon Corp
(DNDN) 41.98

3005 First Avenue, Seattle, WA 98121

Dendreon is at the forefront of introducing the first in a new class of therapy known as Active Cellular Immunotherapies (ACIs). The goal of Active Cellular Immunotherapy is to turn the immune system "back on" to elicit a specific and long-lasting response against cancer. Dendreon's lead ACI candidate, sipuleucel-T, is for the treatment of aysmptomatic, metastatic, androgen-independent prostate cancer.

Eden Bioscience Corp

11816 N. Creek Pkwy. N., Bothell, WA 98011

EDEN BIOSCIENCE® Corporation owns a fundamentally new, patented and proprietary technology called Harp-N-Tek™. EDEN's technology is based on a family of naturally occurring proteins called “harpins” and represent a unique type of crop production tool that EDEN classifies as a plant health regulator. Products containing Harp-N-Tek stimulate a natural plant reaction that activates the internal plant processes controlling disease and stress resistance, growth and reproduction...all processes that contribute to better plant health and improved yields.

Epigenomics
(ECXG.DE) 2.40

Kleine Präsidentenstraße 1, D-10178 Berlin GERMANY Suite 300, 1000 Seneca St, Seattle WASHINGTON 98101

Epigenomics is a molecular diagnostics company focusing entirely on the development and commercialization of in vitro diagnostic tests for cancer screening and cancer specialty applications such as monitoring and classification. Epigenomics’s diagnostic tests detect differences in DNA methylation patterns between healthy and sick individuals as well as between subgroups of patients with different prognoses. Our screening tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma or urine. These tests address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros. Our lead screening test development program is in colorectal cancer. Further screening test are in developement for prostate and lung cancer.

Gilead Sciences, Inc
(GILD) 33.97

333 Lakeside Drive, Foster City, CA 94404 4 University Place 4611 University Drive Durham, NC 27707 650 Cliffside Drive, San Dimas, CA 91773 2025 1st Avenue, Suite 800, Seattle, WA 98121 7575 W. 103rd Avenue, Suite 102, Westminster, CO 80021

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide.

LifeSpan Biosciences

2401 Fourth Avenue, Suite 900, Seattle, WA 98121

LifeSpan is the industry leader in molecular pathology. LifeSpan sells antibodies, immunohistochemistry services and localization databases. Founded in 1995, LifeSpan has developed proprietary antibodies to major classes of drug targets to study the expression of these proteins in normal and diseased human tissues. LifeSpan is also a leader in high-throughput imaging and cancer recognition software and is developing instruments and software for pathology interpretation in preclinical toxicology and cancer diagnostics.

Nanogen, Inc
(NGEN.PK) 0.01

10398 Pacific Center Court, San Diego, CA 92121 21720 23rd Drive SE, #150, Bothell, WA 98021 1 Marmac Drive, Toronto, Ontario, Canada M9W 1E7 Corso Torino 89/d, 10090 Buttigliera Alta (TO), Italy

Nanogen’s technologies are uniquely bridging the gap between early-stage scientific research and actual clinical practice. We are committed to helping the healthcare community realize the benefit of molecular diagnostics and to improving patient care through advances in the diagnosis of disease and the evaluation of particular therapies for individual patients.

Nastech Pharmaceutical Company, Inc.
(MRNA) 2.79

3830 Monte Villa Parkway, Bothell, WA 98021

Nastech Pharmaceutical Company Inc. is a Formulation Science specialty company that utilizes biophysics, physical chemistry and pharmacology to bridge the gap between drug discovery and drug optimization. Nastech’s proprietary Systemic Transnasal Absorption Technology (STA-T™), Paracellular Transport System (PTS™), and Junction Activator Technology (JAT™) provide rapid assessment of the merits of a drug compound for intranasal drug delivery. The Company has a diverse product portfolio across multiple therapeutic areas, including products targeted for the treatment of sexual dysfunction, pain management, cancer and hepatic illnesses, growth deficiency and multiple sclerosis.

Northwest Biotherapeutics, Inc.
(NWBO.OB) 0.94

18701 120TH AVENUE NE, SUITE 101, Bothell, WA 98011

Northwest Biotherapeutics is focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens.

ReachBio LLC
*VENDOR/SERVICE*

454 North 34th St, Seattle, WA 98103

ReachBio provides specialized contract assays, contract research, and educational and consulting services to biopharmaceutical, agrichemical and other life science organizations worldwide. Our focus is on helping our clients expand their own organizations’ capabilities by efficiently harnessing our extensive knowledge and expertise in clinical and industrial stem cell and progenitor cell biology for their benefit. We operate strictly through a fee-for-service model in which the client owns all new intellectual property generated. We offer a variety of standardized contract services based on functional in vitro and in vivo cell biology assays for bone marrow modulation, drug toxicity testing and mechanistic evaluation.

Rosetta Inpharmatics, LLC

401 Terry Avenue N, Seattle, WA 98109

Rosetta Inpharmatics, a wholly owned subsidiary of Merck & Co. Inc., develops and implements technologies that will improve drug discovery. The company's leading-edge genomic research and data analysis efforts focus on how medical compounds affect biology, enabling more accurate selection of drug targets and more efficient drug development.

Seattle Genetics Inc
(SGEN) 12.45

21823 - 30th Drive S.E., Bothell, WA 98021

Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Sonus Pharmauceuticals
(SNUS) 0.00

22026 20th Avenue SE, Bothell, WA 98021

Sonus Pharmaceuticals, Inc. is focused on the development of therapeutic drugs utilizing its proprietary TOCOSOL™ drug delivery technology platform, which features a vitamin-E based oil-in-water emulsion to promote the solubility of lipophilic drugs. The Company is currently applying the TOCOSOL technology to its lead product for cancer therapy, TOCOSOL Paclitaxel. In addition, Sonus is evaluating and developing a number of other potential product candidates in applications to treat cancer, cardiovascular disease, diabetes and infections. Sonus' lead product is TOCOSOL Paclitaxel (S-8184). Paclitaxel is the active ingredient in the world's largest selling anti-cancer drug, Taxol*, which is marketed for the treatment of breast, ovarian and non-small cell lung tumors. TOCOSOL Paclitaxel has been developed to overcome certain limitations of Taxol. The Company believes that TOCOSOL Paclitaxel may have the ability to improve cancer therapy by delivering less toxic and more effective doses of paclitaxel.

Targeted Genetics Corp
(TGEN.PK) 0.40

1100 Olive Way, Suite 100 Seattle, WA 98101

Targeted Genetics Corporation develops and commercializes molecular therapeutics that target the underlying cause of a variety of serious diseases that have significant unmet medical need. Our lead product candidate is being developed as a treatment for inflammatory arthritis, and additional programs target HIV/AIDS, congestive heart failure, Huntington's disease and hyperlipidemia. Our diverse pipeline has been built on a solid foundation of intellectual property related to gene delivery, and on our core capabilities in critical functions that include preclinical development, clinical and regulatory affairs and manufacturing of innovative gene-based product candidates.

Unigen Pharmaceuticals, Inc.

2660 Willamette Drive NE, Lacey, WA 98516

Unigen Pharmaceuticals is a natural products research and development company and proprietary ingredients supplier. The company is dedicated to the discovery of botanically derived therapeutic compounds that address consumer health needs and help improve the quality of human life. Its research and discovery process includes extensive work at both the human cell and gene level. Unigen focuses on identifying and studying the unique ingredients of medicinal botanicals and then formulating proprietary raw materials for use in cosmeceutical, nutraceutical, functional food and pharmaceutical products. Unigen is part of the ECONET global family of health and natural product companies which have operations in the United States, Canada, Korea, Mexico, Russia and China.

Zymogenetics
(ZGEN) 9.76

1201 Eastlake Avenue East, Seattle, WA 98102-3702

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These span a wide array of clinical opportunities, including bleeding, autoimmune and viral diseases and cancer.